Literature DB >> 16055869

A dynamic population model of disease progression in COPD.

M Hoogendoorn1, M P M H Rutten-van Mölken, R T Hoogenveen, M L L van Genugten, A S Buist, E F M Wouters, T L Feenstra.   

Abstract

To contribute to evidence-based policy making, a dynamic Dutch population model of chronic obstructive pulmonary disease (COPD) progression was developed. The model projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025, taking into account population dynamics and changes in smoking prevalence over time. It was estimated that of all diagnosed COPD patients in 2000, 27% had mild, 55% moderate, 15% severe and 3% very severe COPD. The severity distribution of COPD incidence was computed to be 40% mild, 55% moderate, 4% severe and 0.1% very severe COPD. Disease progression was modelled as decline in forced expiratory volume in one second (FEV1) % predicted depending on sex, age, smoking and FEV1 % pred. The relative mortality risk of a 10-unit decrease in FEV1 % pred was estimated at 1.2. Projections of current practice were compared with projections assuming that each year 25% of all COPD patients receive either minimal smoking cessation counselling or intensive counselling plus bupropion. In the projections of current practice, prevalence rates between 2000-2025 changed from 5.1 to 11 per 1,000 inhabitants for mild, 11 to 14 per 1,000 for moderate, 3.0 to 3.9 per 1,000 for severe and from 0.5 to 1.3 per 1,000 for very severe COPD. Costs per inhabitant increased from 1.40 Euro to 3.10 for mild, 6.50 Euro to 9.00 for moderate, 6.20 Euro to 8.50 for severe and from 3.40 Euro to 9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were cost-effective with minimal counselling generating net savings. In conclusion, the chronic obstructive pulmonary disease progression model is a useful instrument to give detailed information about the future burden of chronic obstructive pulmonary disease and to assess the long-term impact of interventions on this burden.

Entities:  

Mesh:

Year:  2005        PMID: 16055869     DOI: 10.1183/09031936.05.00122004

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  Application of a theoretical model to evaluate COPD disease management.

Authors:  Karin M M Lemmens; Anna P Nieboer; Maureen P M H Rutten-Van Mölken; Constant P van Schayck; Javier D Asin; Jos A M Dirven; Robbert Huijsman
Journal:  BMC Health Serv Res       Date:  2010-03-26       Impact factor: 2.655

2.  Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes.

Authors:  Zafar Zafari; Kristian Thorlund; J Mark FitzGerald; Carlo A Marra; Mohsen Sadatsafavi
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

3.  Moving beyond a limited follow-up in cost-effectiveness analyses of behavioral interventions.

Authors:  Rilana Prenger; Marcel E Pieterse; Louise M A Braakman-Jansen; Job van der Palen; Lieke C A Christenhusz; Erwin R Seydel
Journal:  Eur J Health Econ       Date:  2012-01-06

4.  Patient-centered appointment scheduling using agent-based simulation.

Authors:  Ayten Turkcan; Tammy Toscos; Brad N Doebbeling
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

5.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

6.  Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.

Authors:  Justin C Earp; Debra C Dubois; Diana S Molano; Nancy A Pyszczynski; Craig E Keller; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2008-04-30       Impact factor: 4.030

7.  A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Floortje E van Nooten; Marion Lindemann; Manfred Caeser; Peter M A Calverley
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study.

Authors:  Robert M Shavelle; David R Paculdo; Scott J Kush; David M Mannino; David J Strauss
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

9.  Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.

Authors:  Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Mohsen Sadatsafavi; J Mark FitzGerald; Bruce McManus; Don Sin
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

Review 10.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.